This report aims to provide detailed insights into the global apoptosis
assays market. It provides valuable information on the type, procedure,
application, and region in the market. Furthermore, the information for these
segments, by region, is also presented in this report. Leading players in the
market are profiled to study their product offerings and understand the
strategies undertaken by them to be competitive in this market.
Revenue Growth Analysis:
The global apoptosis assays
market is projected to reach USD 5.9 billion by 2023 from USD 3.6 billion in
2018, at a CAGR of 10.5%.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9069428
Key Factors Driving Market Growth:
The major factors driving the growth of this
market include the rising incidence and prevalence of chronic and infectious
diseases, growing funding for cancer research, growing cell-based research, and
development of apoptosis-modulating drugs.
By product, the Assay kits segment is expected to account for the largest
share of the Apoptosis Assays Market in 2018
On the basis of product, assay kits segment is expected to account for the
largest share of the Apoptosis Assays Market in 2018. Assay kits are widely
used in life sciences research, drug discovery and development, and
environmental monitoring in a broad range of applications such as studying
disease pathways, screening for potential drug candidates, and evaluating
biopharmaceutical production processes. This large share can be attributed to
the repeated consumption of assay kits as consumables in various apoptosis
testing processes.
By application, the drug discovery & development application segment is
projected to have the largest market share during the forecast period
Based on application, the Apoptosis Assays Market is segmented into drug
discovery & development, clinical & diagnostic applications, basic
research, and stem cell research. In 2018, the drug discovery & development
application segment is expected to account for the largest share of the global
Apoptosis Assays Industry. The large share of this segment can be attributed to
the rising incidence and prevalence of chronic and infectious diseases and
increasing government support for developing new treatments for various human
diseases.
By end user, the pharmaceutical and biotechnology companies segment is is
projected to have the largest market share during the forecast period
On the basis of end user, the Apoptosis Assays Market is segmented into
pharmaceutical and biotechnology companies, hospital and diagnostic
laboratories, and academic and research institutes. The pharmaceutical and
biotechnology companies segment is expected to account for the largest share in
2018. The large share of this segment can be attributed to the increasing
number of R&D activities undertaken by these companies for the development
of biopharmaceutical products.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=9069428
Regional Growth Analysis:
North America is expected to account for the largest share of the
Apoptosis Assays Market in 2018, followed by Europe and Asia Pacific. The rising incidence and prevalence of
chronic and infectious diseases, a large number of life science research
studies conducted in the region, favorable government support in the form of
research investments, and presence of high-quality infrastructure for clinical
and laboratory research are the major factors responsible for the large share
of the North American Apoptosis Assays Industry.
Key Players:
The prominent players in the Apoptosis Assays Market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad
Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US),
Sartorius AG (Germany), Danaher Corporation
(US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US),
BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium
(US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).
Contact: